Systaaq Diagnostic Products — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Systaaq is a private, commercial-stage diagnostics company focused on providing molecular testing solutions for infectious diseases. Its core offerings include real-time PCR kits for pathogens like HIV, HBV, HCV, and SARS-CoV-2, alongside nucleic acid extraction products and master mixes. The company leverages a flexible development model, claiming the ability to create new tests in under 30 days, and serves medium-to-high throughput testing laboratories globally. Systaaq emphasizes customer-focused, custom solutions and technical support, positioning itself as a nimble player in the molecular diagnostics market.

Infectious Diseases

Technology Platform

Real-time PCR and nucleic acid extraction technology for molecular diagnostics, with capabilities for rapid assay development (under 30 days). Products include extraction kits, universal master mixes, and CE-marked qPCR assay kits.

Opportunities

Growth in global demand for molecular infectious disease testing, especially in medium-high throughput labs seeking cost-effective alternatives to large corporations.

The ability to rapidly develop assays (claimed <30 days) presents a significant opportunity in pandemic preparedness and response to emerging pathogens.

Risk Factors

Faces intense competition from large, established diagnostics firms with greater resources and brand recognition.

Regulatory hurdles, including the lack of FDA approval for the US market, limit growth potential.

Reliance on PCR technology exposes the company to disruption from newer diagnostic platforms.

Competitive Landscape

Operates in the highly competitive molecular diagnostics market, competing against global giants like Roche, Abbott, Qiagen, and Hologic. Systaaq's differentiation is based on customer-focused custom solutions, rapid development claims, and direct technical support, rather than technological breakthrough or scale.

More companies in Diagnostics & Precision Medicine →More companies in United States →